A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", Abraxane, locally advanced, neoadjuvant, paclitaxel | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 